Predictionof Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
An increasing number of research evidences indicate linkage between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD); the two most common diseases of aging. In addition, T2DM and AD also share some common pathophysiological features. Therefore, dual therapy that targets both the diseases can be regarded as a beneficial approach. Acetylcholinesterase (AChE) and beta-secretase (BACE) have been considered as potential therapeutic targets for AD. Accordingly, the piece of work presented here describes the binding of anti-diabetic drugs (Jardiance, Suiny and Nesina) with AChE and BACE so as to further investigate connecting bridges concerning the treatment of these two diseases. We have used "Autodock 4.2" for docking experiments. Both, hydrogen bond and hydrophobic interactions were found to be involved in the proper positioning of these diabetic drugs within the catalytic site (CAS) of AChE and BACE enzymes to permit docking. Free energy of binding (ΔG) for 'Jardiance-AChE', 'uiny-AChE' and 'Nesina-AChE' CAS interactions were found to be -9.21, -7.32 and -10.66 kcal/mol, respectively; while for 'Jardiance-BACE', 'Suiny -BACE' and 'Nesina-BACE' CAS interactions the same were determined to be -8.91, -8.58 and -10.40 kcal/mol, respectively. Hence, these diabetic drugs might act as potent dual inhibitors for the treatment of diabetes-associated neurological disorders. Consequently, the results described herein may form the basis of future dual therapy against the same.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As for other SGLT2i, the Ki for inhibiting AChE is 0.177 µM for empagliflozin and 25.02 µM for dapagliflozin, and brain concentrations are 0.5 µM and 0.3 µM, respectively, so out of those two, only in the case of empagliflozin, brain concentration is enough to inhibit AChE (Table 1) [17,30,60].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [30]
In the citing paper
“As for other SGLT2i, the Ki for inhibiting AChE is 0.177 µM for empagliflozin and 25.02 µM for dapagliflozin, and brain concentrations are 0.5 µM and 0.3 µM, respectively, so out of those two, only in the case of empagliflozin, brain concentration is enough to inhibit AChE (Table 1) [17,30,60].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [30]
Citations
Cites
SwissDock, a protein-small molecule docking web service based on EADock DSS
Grosdidier, A., Zoete, V., & Michielin, O. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr366 · Cited by 1,950
Translating cell biology into therapeutic advances in Alzheimer's disease
Selkoe, D. J. (1999) · Nature · doi:10.1038/399a023 · Cited by 1,166
Structure of the Protease Domain of Memapsin 2 (β-Secretase) Complexed with Inhibitor
Hong, L., Koelsch, G., Lin, X., Wu, S., Terzyan, S., Ghosh, A. K., Zhang, X. C., & Tang, J. (2000) · Science · doi:10.1126/science.290.5489.150 · Cited by 711
Baker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., & Craft, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.225 · Cited by 639
Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama Study
Matsuzaki, T., Sasaki, K., Tanizaki, Y., Hata, J., Fujimi, K., Matsui, Y., Sekita, A., Suzuki, S. O., Kanba, S., Kiyohara, Y., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181eee25f · Cited by 432
Common pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
The relationship between Alzheimer's disease and diabetes: Type 3 diabetes?
Kroner, Z. (2009) · PubMed · Cited by 329
Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment
Li, X., Leng, S., & Song, D. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s74042 · Cited by 292
The role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 272
Cited by
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
“3 μM, respectively, so out of those two, only in the case of empagliflozin, brain concentration is enough to inhibit AChE (Table 1) [17,30,60].”
BackgroundSamman, W. A., Selim, S., Fayoumi, H. M. E., El-Sayed, N. M., Mehanna, E. T., & Hazem, R. M. (2023) · Pharmaceuticals · doi:10.3390/ph16050753 · Cited by 57
Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder
Nakhal, M. M., Aburuz, S., Sadek, B. S., & Akour, A. A. (2022) · Molecules · doi:10.3390/molecules27217174 · Cited by 33
Nakhal, M. M., Jayaprakash, P., Aburuz, S., Sadek, B. S., & Akour, A. A. (2023) · Pharmaceuticals · doi:10.3390/ph16050769 · Cited by 26
Molecular docking analysis of phytochemicals with estrogen receptor alpha
Rafeeq, M. M. (2022) · Bioinformation · doi:10.6026/97320630018697 · Cited by 17
Metadata
- Authors
- Shaikh, S., Rizvi, S. M., Suhail, T., Shakil, S., Abuzenadah, A., Anis, R., Naaz, D., Dallol, A., Haneef, M., Ahmad, A., & Choudhary, L.
- Affiliations
- King Abdulaziz University (SA)
- ORCID
- Venue
- CNS & Neurological Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2016-10-18
- Volume
- 15
- Issue
- 10
- Pages
- 1216-1221
- ISSN
- 1568-007X (ISSN-L)
- 1871-5273
- OpenAlex
- W2527997118
- Cited by
- 10
- References
- 30
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 3 · 2021: 2 · 2019: 1
- FWCI
- 0.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS & Neurological Disorders - Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- antidiabetic drugs, acetylcholinesterase, beta-secretase, dual inhibitors, Alzheimer's disease, type 2 diabetes, SGLT2 inhibitors, drug-target binding, binding free energy, dual therapy
- MeSH terms
- Acetylcholinesterase, Alzheimer Disease, Diabetes Mellitus, Type 2, Enzyme Inhibitors, Humans, Hypoglycemic Agents, Models, Molecular, Computational Biology, Amyloid Precursor Protein Secretases, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predictionof Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study. https://app.cochat.ai/papers/10.2174/1871527315666161003125752
- The paper
- Shaikh, S., Rizvi, S. M., Suhail, T., Shakil, S., Abuzenadah, A., Anis, R., Naaz, D., Dallol, A., Haneef, M., Ahmad, A., & Choudhary, L. (2016). Predictionof Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527315666161003125752
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.